|

silevertinib in combination with temozolomide Clinical Trials

1 actively recruiting trial across 1 location

No change since July 2026

Also known as: BDTX-1535, TMZ, Temodar

Pipeline

Phase 2: 1

Top Sponsors

  • Black Diamond Therapeutics, Inc.1

Indications

  • Newly Diagnosed Glioblastoma1
  • Central Nervous System Diseases1
  • Glioblastoma Multiforme (GBM)1
  • Glioblastoma (GBM)1
  • GBM1

Birmingham, Alabama1 trial

Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

University of Alabama at Birmingham O'Neal Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.